Steven Cohen’s Lexicon Pharmaceuticals LXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.8M Buy
8,251,325
+436,719
+6% +$851K 0.02% 896
2026
Q1
$12.2M Buy
7,814,606
+7,530,581
+2,651% +$11M 0.02% 1111
2025
Q4
$327K Buy
+284,025
New +$390K ﹤0.01% 3443
2025
Q1
Sell
-8,988,421
Closed -$6.64M 2326
2024
Q4
$6.64M Buy
8,988,421
+7,758,371
+631% +$9.35M 0.01% 856
2024
Q3
$1.93M Sell
1,230,050
-2,891,141
-70% -$5.15M ﹤0.01% 1208
2024
Q2
$6.92M Buy
4,121,191
+3,536,805
+605% +$6.34M 0.02% 745
2024
Q1
$1.4M Buy
+584,386
New +$1.26M ﹤0.01% 1377
2023
Q2
Sell
-516,367
Closed -$1.25M 2519
2023
Q1
$1.25M Sell
516,367
-827,764
-62% -$1.9M ﹤0.01% 1066
2022
Q4
$2.57M Sell
1,344,131
-2,269,369
-63% -$4.83M 0.01% 892
2022
Q3
$8.67M Buy
+3,613,500
New +$10M 0.03% 546
2019
Q4
Sell
-528,100
Closed -$1.59M 1120
2019
Q3
$1.59M Buy
+528,100
New +$1.64M 0.01% 622
2017
Q2
Sell
-382,500
Closed -$5.49M 933
2017
Q1
$5.49M Buy
+382,500
New +$5.68M 0.03% 509

Other funds holding LXRX

Steven Cohen's LXRX Position: Q2 2026 in Review

Steven Cohen increased its Lexicon Pharmaceuticals (LXRX) stake by 5.6% in Q2 2026, buying an estimated $851K and bringing the position to 8,251,325 shares worth $19.8M. The position accounts for 0.02% of the portfolio, ranked #896.

Steven Cohen first reported a position in LXRX in Q1 2017 and has held it in 12 quarters since. 148 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Steven Cohen held 8,251,325 shares of Lexicon Pharmaceuticals worth $19.8M as of Q2 2026.
  • Steven Cohen bought 436,719 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $851K.
  • Lexicon Pharmaceuticals made up 0.02% of Steven Cohen's portfolio in Q2 2026, its #896 holding.
  • Steven Cohen first reported a position in Lexicon Pharmaceuticals in Q1 2017 and has held it in 12 quarters since.
  • 148 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.